Esperion Therapeutics, Inc. is a pharmaceutical company. Co. is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Co.'s products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Co.'s NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). We show 35 historical shares outstanding datapoints in our ESPR shares outstanding history coverage, used to compute ESPR market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ESPR market cap history over the course of time is important for investors
interested in comparing ESPR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ESPR versus a peer is one thing; comparing
ESPR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ESPR can fluctuate over the course of history.
With this page we aim to empower investors researching ESPR by allowing them to research the ESPR market cap history. |
Free ESPR Email Alerts:
Video: The Importance of Market Cap
